L&G Healthcare Technology & Innovation UCITS ETF Accum Shs USDL&G Healthcare Technology & Innovation UCITS ETF Accum Shs USDL&G Healthcare Technology & Innovation UCITS ETF Accum Shs USD

L&G Healthcare Technology & Innovation UCITS ETF Accum Shs USD

No trades
See on Supercharts

Key stats


Assets under management (AUM)
‪81.08 M‬EUR
Fund flows (1Y)
‪16.65 M‬EUR
Dividend yield (indicated)
Discount/Premium to NAV
0.6%
Shares outstanding
‪6.31 M‬
Expense ratio
0.49%

About L&G Healthcare Technology & Innovation UCITS ETF Accum Shs USD


Brand
L&G
Inception date
Jun 17, 2019
Structure
Irish VCIC
Index tracked
ROBO Global Healthcare Technology and Innovation ETF
Replication method
Physical
Management style
Passive
Dividend treatment
Capitalizes
Primary advisor
LGIM Managers (Europe) Ltd.
ISIN
IE00BK5BC677
The L&G Healthcare Breakthrough UCITS ETF (the ETF) aims to track the performance of the ROBO Global Healthcare Technology and Innovation Index TR (the Index).

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Broad-based
Strategy
Vanilla
Geography
Global
Weighting scheme
Market cap
Selection criteria
Market cap

Returns


1 month3 monthsYear to date1 year3 years5 years
Price performance
NAV total return

What's in the fund


As of September 19, 2025
Exposure type
StocksBonds, Cash & Other
Health Technology
Stocks99.96%
Health Technology82.67%
Technology Services5.45%
Commercial Services4.76%
Health Services4.04%
Distribution Services1.77%
Electronic Technology1.27%
Bonds, Cash & Other0.04%
Cash0.04%
Stock breakdown by region
77%18%4%
North America77.86%
Europe18.00%
Asia4.13%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings

Dividends


Dividend payout history

Assets under management (AUM)



Fund Flows



Frequently Asked Questions


XMLH invests in stocks. The fund's major sectors are Health Technology, with 82.67% stocks, and Technology Services, with 5.45% of the basket. The assets are mostly located in the North America region.
XMLH top holdings are CRISPR Therapeutics AG and Natera, Inc., occupying 2.34% and 2.11% of the portfolio correspondingly.
XMLH assets under management is ‪81.08 M‬ EUR. It's risen 2.37% over the last month.
XMLH fund flows account for ‪16.65 M‬ EUR (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
No, XMLH doesn't pay dividends to its holders.
XMLH shares are issued by Legal & General Group Plc under the brand L&G. The ETF was launched on Jun 17, 2019, and its management style is Passive.
XMLH expense ratio is 0.49% meaning you'd have to pay 0.49% of your investment to help manage the fund.
XMLH follows the ROBO Global Healthcare Technology and Innovation ETF. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
XMLH invests in stocks.
XMLH price has risen by 0.67% over the last month, and its yearly performance shows a −0.49% decrease. See more dynamics on XMLH price chart.
NAV returns, another gauge of an ETF dynamics, have fallen by −0.33% over the last month, showed a 10.21% increase in three-month performance and has decreased by −0.17% in a year.
XMLH trades at a premium (0.45%) meaning the ETF is trading at a higher price than the calculated NAV.